Mpm Bioventures 2018, L.P.

CIK: 0001729505

Transaction Breakdown

Open Market Buys (P)1 (6.3%)

High conviction signal

Open Market Sales (S)12 (75.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)0 (0.0%)

Compensation grants

Other (G, F, J, C, D, …)3 (18.8%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

TRDA

Entrada Therapeutics, Inc.

10% Owner

AKTS

Aktis Oncology, Inc.

10% Owner

ITOS

iTeos Therapeutics, Inc.

Discretionary Trading P&L

Holdings

Transaction History (16 total)

TRDA
Entrada Therapeutics, Inc.
Sep 9, 2026
Sale(S)
Indirect
28.8K shares at avg. $7.13$206K
TRDA
Entrada Therapeutics, Inc.
Sep 8, 2026
Sale(S)
Indirect
192.5K shares at avg. $7.41$1.4M
TRDA
Entrada Therapeutics, Inc.
Sep 4, 2026
Sale(S)
Indirect
38.5K shares at avg. $7.11$274K
TRDA
Entrada Therapeutics, Inc.
Sep 3, 2026
Sale(S)
Indirect
32.3K shares at avg. $7.17$231K
TRDA
Entrada Therapeutics, Inc.
Sep 2, 2026
Sale(S)
Indirect
25.1K shares at avg. $7.19$181K
TRDA
Entrada Therapeutics, Inc.
Sep 1, 2026
Sale(S)
Indirect
29.1K shares at avg. $7.06$205K
TRDA
Entrada Therapeutics, Inc.
Aug 26, 2026
Sale(S)
Indirect
14.6K shares at avg. $7.06$103K
TRDA
Entrada Therapeutics, Inc.
Aug 25, 2026
Sale(S)
Indirect
26.5K shares at avg. $7.54$200K
TRDA
Entrada Therapeutics, Inc.
Aug 24, 2026
Sale(S)
Indirect
21.6K shares at avg. $7.34$159K
AKTS
Aktis Oncology, Inc.
Jan 12, 2026
Conversion(C)
Indirect
1.3M shares-
AKTS
Aktis Oncology, Inc.
Jan 12, 2026
Conversion(C)
Indirect
5.9M shares-
AKTS
Aktis Oncology, Inc.
Jan 12, 2026
Conversion(C)
Indirect
1.6M shares-
AKTS
Aktis Oncology, Inc.
Jan 12, 2026
Purchase(P)
Indirect
1.1M shares at avg. $18.00$20.0M
ITOS
iTeos Therapeutics, Inc.
May 13, 2025
Sale(S)
Indirect
630.2K shares at avg. $8.06$5.1M
TRDA
Entrada Therapeutics, Inc.
Dec 11, 2024
Sale(S)
Indirect
21.8K shares at avg. $20.23$441K
TRDA
Entrada Therapeutics, Inc.
Dec 10, 2024
Sale(S)
Indirect
22.9K shares at avg. $20.77$476K

		Type	Shares	Price		Ownership
Sep 9, 2026	TRDA Entrada Therapeutics, Inc.	Sale(S)	28,837	$7.13	$205,608	Indirect
Sep 8, 2026	TRDA Entrada Therapeutics, Inc.	Sale(S)	192,500	$7.41	$1,426,425	Indirect
Sep 4, 2026	TRDA Entrada Therapeutics, Inc.	Sale(S)	38,500	$7.11	$273,735	Indirect
Sep 3, 2026	TRDA Entrada Therapeutics, Inc.	Sale(S)	32,263	$7.17	$231,326	Indirect
Sep 2, 2026	TRDA Entrada Therapeutics, Inc.	Sale(S)	25,131	$7.19	$180,692	Indirect
Sep 1, 2026	TRDA Entrada Therapeutics, Inc.	Sale(S)	29,088	$7.06	$205,361	Indirect
Aug 26, 2026	TRDA Entrada Therapeutics, Inc.	Sale(S)	14,569	$7.06	$102,857	Indirect
Aug 25, 2026	TRDA Entrada Therapeutics, Inc.	Sale(S)	26,522	$7.54	$199,976	Indirect
Aug 24, 2026	TRDA Entrada Therapeutics, Inc.	Sale(S)	21,623	$7.34	$158,713	Indirect
Jan 12, 2026	AKTS Aktis Oncology, Inc.	Conversion(C)	1,314,262	-	$0	Indirect
Jan 12, 2026	AKTS Aktis Oncology, Inc.	Conversion(C)	5,914,197	-	$0	Indirect
Jan 12, 2026	AKTS Aktis Oncology, Inc.	Conversion(C)	1,577,119	-	$0	Indirect
Jan 12, 2026	AKTS Aktis Oncology, Inc.	Purchase(P)	1,112,777	$18.00	$20,029,986	Indirect
May 13, 2025	ITOS iTeos Therapeutics, Inc.	Sale(S)	630,191	$8.06	$5,079,339	Indirect
Dec 11, 2024	TRDA Entrada Therapeutics, Inc.	Sale(S)	21,787	$20.23	$440,751	Indirect
Dec 10, 2024	TRDA Entrada Therapeutics, Inc.	Sale(S)	22,935	$20.77	$476,360	Indirect

1-16 of 16 transactions

About MPM BIOVENTURES 2018, L.P.

MPM BIOVENTURES 2018, L.P. (SEC CIK 0001729505) files insider reports with the SEC as 10% Owner of Entrada Therapeutics, Inc. (TRDA), 10% Owner of Aktis Oncology, Inc. (AKTS) and iTeos Therapeutics, Inc. (ITOS).

Signal8 holds 7 ownership filings by MPM BIOVENTURES 2018, L.P. (1 Form 3, 6 Form 4), filed between Dec 12, 2024 and Sep 9, 2026. Those filings report 16 transactions, from Dec 10, 2024 to Sep 9, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on MPM BIOVENTURES 2018, L.P.'s filings is in BOSTON, MA.

Recent filings by MPM BIOVENTURES 2018, L.P.

Sep 9, 2026: Open-market sale of TRDA shares (Form 4, code S).
Sep 8, 2026: Open-market sale of TRDA shares (Form 4, code S).
Sep 4, 2026: Open-market sale of TRDA shares (Form 4, code S).
Sep 3, 2026: Open-market sale of TRDA shares (Form 4, code S).
Sep 2, 2026: Open-market sale of TRDA shares (Form 4, code S).

Other insiders filing for Entrada Therapeutics, Inc. (TRDA)

MPM BioVentures 2014, L.P., 10% Owner
Doshi Dipal, CEO
Dowden Nathan J, President & COO
Sethuraman Natarajan, President, Research & Develop.
WENTWORTH KORY JAMES, Chief Financial Officer
PARMAR KUSH, Director

How to read Form 4 transaction codes